Enlaces de acceso:
CONTENIDO
Destacados
-
Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy.
Kesselring AM, Wit FW, Sabin CA, Lundgren JD, Gill MJ, Gatell JM, Rauch A, Montaner JS, de Wolf F, Reiss P, Mocroft A; Nevirapine Toxicity Multicohort Collaboration.AIDS 23(13):1689-1699
-
HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins.
Brumme, Z.L., M. John, J.M. Carlson, C.J. Brumme, D. Chan, M.A. Brockman, L.C. Swenson, I. Tao, S. Szeto, P. Rosato, J. Sela, C.M. Kadie, N. Frahm, C. Brander, D.W. Haas, S.A. Riddler, R. Haubrich, B.D. Walker, P.R. Harrigan, D. Heckerman, and S. Mallal.PLoS One 4:e6687.
-
The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates.
Buzon, M. J., Dalmau, J., Puertas, M. C., Puig, J., Clotet, B., and Martinez-Picado, J.Aids 2010 24 (1): 17-25
-
Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility
Puertas, M. C., Buzon, M. J., Artese, A., Alcaro, S., Menendez-Arias, L., Perno, C. F., Clotet, B., Ceccherini-Silberstein, F., and Martinez-Picado, J.J Virol 83, 7434-7439
-
Kaposi sarcoma-associated herpesvirus (KSHV) seroprevalence in population-based samples of African children: evidence for at least 2 patterns of KSHV transmission.
Butler, L.M., G. Dorsey, W. Hladik, P.J. Rosenthal, C. Brander, T.B. Neilands, G. Mbisa, D. Whitby, P. Kiepiela, A. Mosam, S. Mzolo, S.C. Dollard, and J.N. MartinJ Infect Dis 200:430-438.
